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Abstract
Background
Reports on medium and long-term sequelae of SARS-CoV-2 infections largely lack quantification of incidence and relative risk. We describe the rationale and methods of the Innovative Support for Patients with SARS-CoV-2 Registry (INSPIRE) that combines patientreported outcomes with data from digital health records to understand predictors and
impacts of SARS-CoV-2 infection.

Methods
INSPIRE is a prospective, multicenter, longitudinal study of individuals with symptoms of
SARS-CoV-2 infection in eight regions across the US. Adults are eligible for enrollment if
they are fluent in English or Spanish, reported symptoms suggestive of acute SARS-CoV-2
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infection, and if they are within 42 days of having a SARS-CoV-2 viral test (i.e., nucleic acid
amplification test or antigen test), regardless of test results. Recruitment occurs in-person,
by phone or email, and through online advertisement. A secure online platform is used to
facilitate the collation of consent-related materials, digital health records, and responses to
self-administered surveys. Participants are followed for up to 18 months, with patientreported outcomes collected every three months via survey and linked to concurrent digital
health data; follow-up includes no in-person involvement. Our planned enrollment is 4,800
participants, including 2,400 SARS-CoV-2 positive and 2,400 SARS-CoV-2 negative participants (as a concurrent comparison group). These data will allow assessment of longitudinal
outcomes from SARS-CoV-2 infection and comparison of the relative risk of outcomes in
individuals with and without infection. Patient-reported outcomes include self-reported
health function and status, as well as clinical outcomes including health system encounters
and new diagnoses.

Results
Participating sites obtained institutional review board approval. Enrollment and follow-up are
ongoing.

Conclusions
This study will characterize medium and long-term sequelae of SARS-CoV-2 infection
among a diverse population, predictors of sequelae, and their relative risk compared to persons with similar symptomatology but without SARS-CoV-2 infection. These data may
inform clinical interventions for individuals with sequelae of SARS-CoV-2 infection.

Introduction
The COVID-19 pandemic is associated with considerable morbidity and mortality. As of
December 2021, > 51 million COVID-19 cases and > 805,000 attributed deaths have been
detected in the USA [1]. Globally, > 276 million COVID-19 cases and > 5.3 million attributed
deaths have been reported [2]. The clinical course of acute COVID-19 is well-described [3–7].
According to the Centers for Disease Control, post-acute COVID-19 is defined as emergent,
recurring or persistent symptoms occurring � 4 weeks following acute infection with COVID19 (https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html). Other sources
describe post-acute COVID-19 as persistence of symptoms or development of sequelae after 3
or 4 weeks from the onset of acute symptoms of COVID-19 [8–10]. Some have divided the
post-acute time period into subacute period (4–12 weeks) beyond acute COVID-19, and a
chronic or post-COVID-19 syndrome (> 12 weeks), which includes symptoms persisting or
present not attributable to alternative diagnoses [8, 11]. Information on post-acute COVID-19
and long-term sequelae of SARS-CoV-2 infection has continued to emerge [12–15].
To characterize post-COVID-19 syndromes better, there is an urgent need greater diversity
in the study population to allow for representativeness and generalizability, to set objective
outcomes that are not limited to symptoms but include illness events and clinical events, and
to include SARS-CoV-2 negative individuals to ensure other effects of the pandemic are considered in the analysis (e.g. impact on livelihoods, mental health, food security, and mobility)
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[16]. Such work will help clinicians know what post-infectious sequelae to expect and who is at
increased risk, will help ensure research findings can be compared across studies, and will
move us towards addressing critical health care response needs.
To accelerate research during this critical time in the global COVID-19 pandemic, our
research consortium designed a prospective longitudinal study to use patient-reported information linked to real-world data through the Innovative Support for Patients With SARS-COV2 Infections Registry (INSPIRE) hosted on a secure online platform (Hugo, Hugo Health
LLC, Guilford, CT) which imports health information from various sources with permission
from participants. In this study, researchers follow a sample of individuals under investigation
for SARS-CoV-2 over time, to collect patient-reported outcomes, interactions with the medical
system (i.e., clinic visits, hospitalizations, laboratory test and medications prescribed) and outcomes of care as reported in the electronic medical record (EMR). The goals of this research
are to understand the medium- and long-term sequelae of symptomatic SARS-CoV-2 infection, to describe predictors of sequelae as reported by individuals and as recorded in their
EMR, and to assess the intersection of long-term sequelae of COVID-19 with other previously
defined syndromes with overlapping features such as myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS).

Methods
Study design
This is a prospective, multicenter, longitudinal cohort study of individuals with acute symptoms consistent with SARS-CoV-2, including those with positive and negative diagnostic
SARS-CoV-2 tests to compare those with and without SARS-CoV-2 infection (ClinicalTrials.
gov Identifier: NCT04610515) [17].

Setting
Participants are enrolled from one of eight regions across the United States led by investigators
at Rush University (Chicago, Illinois), Yale University (New Haven, Connecticut), the University of Washington (Seattle, Washington), Thomas Jefferson University (Philadelphia, Pennsylvania), the University of Texas Southwestern (Dallas, Texas), the University of Texas,
Houston (Houston, Texas), the University of California, San Francisco (San Francisco, California) and the University of California, Los Angeles (Los Angeles County, California). The
recruitment areas vary in terms of the population served to allow for ethnic and geographic
diversity among study participants. As enrollment is through the internet and can be completed without assistance of research staff support, participants include those who have never
been to the clinic or hospital for their symptoms and others who have been to the emergency
department or hospitalized. Additionally, participants with any digital health portal can enroll
in this study; participants’ health portals need not be those directly linked to the academic
institutions listed above.

Participants
This study includes adult patients who are under clinical investigation for possible SARS-CoV-2 infection and who meet inclusion criteria outlined in Table 1. We include individuals
with symptomatic presentation to determine comparative frequency of outcomes amongst
symptomatic individuals with and without SARS-CoV-2 infection: symptomatic individuals
presenting with covid-like illness who test negative will act as controls for symptomatic individuals who have positive tests for SARS-CoV-2. Asymptomatic individuals are not eligible,

PLOS ONE | https://doi.org/10.1371/journal.pone.0264260 March 3, 2022

3 / 19

PLOS ONE

INSPIRE study

Table 1. Inclusion and exclusion criteria.
Inclusion criteria:
a) Fluent in English or Spanish
b) Age 18 years or older
c) At least one self-reported symptom(s) suggestive of acute SARS-CoV-2 infection [19]
d) Tested for SARS-CoV-2 with any FDA-approved or authorized viral test (i.e., nucleic acid amplification test or
antigen test [20]) within 42 days of enrollment
Exclusion criteria:
a) Unable to provide informed consent
b) Study team unable to confirm the result of a diagnostic test for SARS-CoV-2
c) Does not have access to a hand-held device or computer that would allow for digital participation in the
study
d) Lawfully imprisoned while participating in the study
https://doi.org/10.1371/journal.pone.0264260.t001

given the anticipated lower rates of outcomes among asymptomatic individuals who test positive for SARS-CoV-2, and the significant heterogeneity in reasons for testing in asymptomatic
individuals, such as screening for social, educational, occupational reasons and prior to routine
clinical procedures. Individuals who self-report symptoms suggestive of acute SARS-CoV-2
infection, and are tested for SARS-CoV-2 within the last 42 days, are eligible to participate.
From study initiation through the summer of 2021, symptoms of acute SARS-CoV-2 were
defined using the COVID-19 clinical criteria case definition [18]; beginning August of 2021, in
order to capture less symptomatic individuals, the inclusion criteria were revised to require
only one symptom among those listed in Table 2. Individuals for whom a SARS-CoV-2 test
result cannot be confirmed are not eligible to participate in the study. Efforts are made to
recruit participants from across the spectrum of COVID-19 illness severity, including individuals from outpatient (e.g., drive through testing with self-reported symptoms) to inpatient settings, and those cared for in intensive care units. We initially used a 3:1 case/control
enrollment ratio to oversample those who are positive for SARS-CoV-2 on testing, while still
Table 2. List of COVID-19 like symptoms used to determine study enrollment eligibility.
Participants are asked, “Since you first felt sick with COVID-19 like symptoms, have you had any of the following?”
Note: presence of at a least one symptom is required for study participation
• Fever (>100.4F [38C])
• Feeling hot or feverish
• Chills
• Repeated shaking with chills
• More tired than usual
• Muscle aches
• Joint pains
• Runny nose
• Sore throat
• A new cough, or worsening of a chronic chough
• Shortness of breath
• Wheezing
• Pain or tightness in your chest
• Palpitations
• Nausea or vomiting
• Headache
• Hair loss
• Abdominal pain
• Diarrhea (>3 loose/looser than normal stools/24 hours)
• Decreased smell or change in smell
• Decreased taste or change in taste
https://doi.org/10.1371/journal.pone.0264260.t002
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ensuring an adequate control cohort for comparison. However, given the heterogeneity in
baseline characteristics among study subjects, we modified the enrollment to support a 1:1
case/control ratio, which will better enable the comparison of ‘like’ cases with ‘like’ controls.
Participant identification and enrollment. Methods used to recruit potentially eligible
participants vary by site, although each site applies the same eligibility criteria described in
Table 1. Most sites screen for eligible participants among those tested for SARS-CoV-2 infection. We seek to enroll participants as close to their initial date of SARS-CoV-2 testing as possible in order to reduce recall bias. Participant identification and recruitment methods include:
i) participants learn of the study from a poster, brochure, or social media advertisement and/
or ii) research staff identify potentially eligible individuals and reach out to them in-person,
over the phone (e.g., text or call), or by e-mail to invite them to enroll. In some instances,
members of the study team access the EMR to screen for eligible individuals based on SARS-CoV-2 testing and reason for testing. In other cases, contact information are obtained from
organizations conducting SARS-CoV-2 testing. The recruitment methods used at each site are
based on local IRB approval and practical considerations. Regardless of how the individual is
recruited, all participants must enroll through the online portal. Individuals may access this
portal through any device that connects to the internet (e.g., smart phone, tablet, computer).
Though minor differences exist across sites, the study eligibility criteria, online enrollment,
and data collection methods are identical, which allows for compilation and comparison of
data across sites.

Variables and outcomes
Patient-reported outcomes include self-reported disease-specific and health status outcomes
(Table 3 and S1 Appendix) [21–23]. Health care utilization and clinical events are extracted
from the EMR data via Hugo, ensuring uniform variable definitions across participating sites.
Table 3. Summary of survey variables collected, instrument sources, and schedule of survey delivery.
Variable Type

Instrument Source

Survey schedule
0 (PreEnrollment)

Screening questions

Designed for INSPIRE

X

Socio-demographics

CDC Patient Under Investigation

X

0 (Baseline) 3 6 9 12 15 18

Testing information

CDC Patient Under Investigation

X

Visits to healthcare
facilities

Designed for INSPIRE

X

X X X X

X

X

Symptom check

CDC Patient Under Investigation, case studies

X

X X X X

X

X

Social determinants of
health

CMS Accountable Health Communities Health-Related Social Needs
Screening Tool

X

Physical/mental health

PROMIS-29 v2.1

X

X X X X

X

X

Cognitive Function

PROMIS Cognitive SF 8a

X

X X X X

X

X

Return to work/activity

Designed for INSPIRE

X X X X

X

X

Post-infectious seq

Modified Medical Research Council Dyspnea Scale, Cough Evaluation Test

X

X X X X

X

X

PTSD

Primary Care-PTSD-5

X

X X X X

X

X

Exercise

Exercise vital sign

X

X X X X

X

X

Fatigue symptoms

CDC Short Symptom Screener

X

X X X X

X

X

Severity of Illness

Designed for INSPIRE

X X X X

X

X

Vaccine information

Designed for INSPIRE

X X X X

X

X

Comorbidities

Designed for INSPIRE

X

X

https://doi.org/10.1371/journal.pone.0264260.t003
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SARS-CoV-2 Symptom Questionnaire—derived from the Centers for Disease Control and
Prevention (CDC) Person Under Investigation for SARS-CoV-2 survey (Table 2) [24]. This is
not scored and has no predefined cutoff for the likelihood of COVID-19 illness.
Physical and mental health status is assessed using the PROMIS1-29 survey instrument
[25]. This measure assesses pain intensity using a single 0–10 numeric rating item, and seven
health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety,
ability to participate in social roles and activities, and sleep disturbance) using five response
options per domain ranging from “not at all” to “very much”. In prior studies, this measure
exhibits high reliability and validity, correlating well with other physical and mental health surveys as well as with chronic disease. The PROMIS1 instrument assesses health-related quality
of life over the past seven days, except for two domains (physical function and ability to participate in social roles and activities) which do not specify a timeframe. Raw PROMIS1-29 scores
are re-scaled from raw scores of 8 (worst) to 40 (best) into a standardized T-score with a mean
of 50 and a standard deviation (SD) of 10. A higher PROMIS1 T-score represents more of the
concept being measured. For negatively worded concepts like Anxiety, a higher score is worse.
For positively worded concepts like Physical Function-Mobility, a higher score is better. Version 2.1 of the PROMIS1-29, used in the present study, is rescaled into a generic, societal, preference-based summary score [26]. This is based on PROMIS1 scores for Cognitive Function,
Abilities, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and
Ability to Participate in Social Roles and Activities. It is scaled from 0 (equal to death) to 1
(equal to perfect health). Version 2.0 PROMIS1 scores can also be used to estimate a Health
Utility Index Mark 3 preference score [27]. In other settings, differences of 0.03 to 0.1 in this
preference score have been interpreted as being clinically important [28–30]. A cutoff of 0.7 is
used to determine severe impairment [31].
Cognition is assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS1) Cognitive SF 8 [32]. PROMIS1 Cognitive scores are re-scaled from raw
scores of 8 (worst) to 40 (best) into standardized T-scores with a mean of 50 and standard deviation (SD) of 10. A higher score is interpreted as indicating greater cognition.
Health care process measures are assessed as ambulatory care and/or emergency department (ED) visits for symptoms related to COVID-19 illness as well as hospitalization (admitted to hospital overnight during study follow-up) as determined by data from the EMR.
Hospital-free and intensive care unit (ICU)-free survival are assessed as determined by data
from the EMR [33]. Additionally, follow-up surveys include questions on COVID-19 related
outpatient visits, emergency department visits, hospitalizations and ICU admissions. Hospitalfree survival is defined as survival without any hospitalizations, and ICU-free survival as survival without time spent in the ICU.
Vaccination status, vaccination type, and timing of vaccination is assessed in the baseline
and follow-up surveys. We will also use EMR data to validate vaccination status in a subset of
enrolled participants.
Additional outcomes assessed include post-infectious sequelae (i.e., dyspnea, cough) [34–
36], post-traumatic stress disorder (PC-PTSD-5) [37], and exercise (exercise vital sign; 2 question survey to assess habitual physical activity) [38–40], using previously validated
questionnaires.
Social determinants of health (e.g., housing, available social services, geographical location,
and education) are assessed using a previously validated questionnaire [41].
Work and activity status are assessed using questions about returning to work, missed work
and activity level (S1 Appendix).
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is assessed using the CDC
Short Symptom Screener (S1 Appendix), although there are no validated surveys to assess
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ME-CFS. This survey, however, closely aligns with the 2015 Institute of Medicine diagnostic
criteria for ME-CFS [42]. While the study design will allow for assessment of a range of clinical
outcomes, ME-CFS was of particular interest given early reports that post-COVID sequelae
may overlap with ME/CFS.

Data sources
Results for a SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test) are
confirmed by the research staff either through visualizing the result in the EMR or by reviewing an image of the test result sent to the research staff by the participant. After an eligible
patient enrolls in the study, a combination of self-reported information and information generated from the patient’s own health information is connected to the Hugo platform, collected,
and sent to the study site over the 18-month follow-up period (S1 Appendix).
Self-reported data. Using Hugo, surveys including the variables outlined above are sent
by electronic mail or text to participants at the research site every 3 months throughout the follow-up period (Fig 1). These responses are sent through the Hugo platform and then shared
with the study team. Subjects use their personal smartphone, tablet, computer, or other electronic device to connect to the internet and answer surveys that ascertain their symptoms,
health care use, and physical, mental, and social health over an 18-month period. Responses
sent by participants are encrypted. To minimize participant burden, each data collection episode is designed to take approximately 15 minutes or less to complete.
Patient-centric data sharing. At enrollment, participants connect their health system
portal account/s with the Hugo platform (Fig 2). Hugo is a web-based platform used to longitudinally collect data for this study. The Hugo platform gives patients the ability to collect and
maintain their personal health records in a centralized, cloud-based account. Participants create a Hugo account and connect the health system portal accounts they choose to connect with
the Hugo platform. This may include patient portals from healthcare systems, pharmacies, laboratories, and insurers. Individuals direct Hugo to share their health records with the research
team according to the terms in the informed consent. This information is sent from Hugo to
the research analytic core and stored in accordance with their institutional policies. The specific portal-related information available through Hugo in use for INSPIRE includes all data
available through the patient portal, including medications, appointments and visits, test
orders and results, clinical notes, problems, diagnoses, vital signs, demographics, and immunizations. After the study, participants can maintain their Hugo account or opt to delete their
account and data.
Participants can connect their health system(s) portal accounts with Hugo at set up but may
need assistance if they have technical issues or if they do not complete this initial step at enrollment. Once participants create an account in Hugo and link their portals, no additional
actions are required to stream data into Hugo. Technical support from the enrolling site or
clinical core is provided to resolve any difficulties setting up an account.
During the study, periodically Hugo downloads identifiable data outlined in the IRB protocol and consent form. Research sites have access to site-specific dashboards to track enrollment, identify which data sources are connected, and to monitor survey responses.
Deidentified, individual-level data are sent from Hugo to the analytic team periodically for
quality assurance and analysis.

Human subjects considerations
This study involves self-enrollment with an online consent process using an electronic consent
form designed with easy-to-read language. The consent form is a click-through digital
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Fig 1. Participant timeline.
https://doi.org/10.1371/journal.pone.0264260.g001

document where, after reading the document, the participant clicks to agree or disagree to
study participation.
Electronic consent occurs through the Hugo platform. Participants are eligible to receive a
small incentive for completion of each periodic questionnaire; the total value will be $100 over
the course of the study. Researchers will not provide any information gathered through the
study to clinicians engaged in treating the patient. Patients will be informed and reminded
that their responses will not be provided to their healthcare team, both at the beginning of the
study during the consent process and throughout the study on the regular questionnaires.
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Fig 2. Use of Hugo health to capture participant data.
https://doi.org/10.1371/journal.pone.0264260.g002

Ethics approval of this protocol has been obtained at each individual site including Rush
University (protocol number: 20030902, approved 3/14/2020), Yale University (2000027976,
approved 4/30/2020), the University of Washington (UW Human Subjects Division,
STUDY00009920, approved 4/2/2020), Thomas Jefferson University (20p.1150, approved 1/
21/2021), the University of Texas Southwestern Medical Center (STU 2020–1352, approved 2/
3/2021), the University of Texas, Houston (HSC-MS-20-0981, approved 9/10/2020), the University of California, San Francisco (20–32222, approved 1/25/2021) and the University of California, Los Angeles (20–001683, approved 12/18/2020). The Yale University ethics approval
includes the role as the analytic lead. Additionally, the Rush University ethics approval
includes INSPIRE data storage on the Hugo platform and transfer of data to Rush for secure
storage.

Study size
Our target enrollment at study initiation was 3,600 people with SARS-CoV-2 infection confirmed by a positive SARS-CoV-2 viral test (i.e., nucleic acid amplification test or antigen test)
and 1,200 people with a negative SARS-CoV-2 viral test. We expect that the age distribution of
enrolled subjects will be broadly representative of patients tested in each site. Four of the sites
(Yale, Jefferson, Rush and UW) draw on smaller catchment populations so have planned
enrollment of 400 subjects per site. Four sites (UT Southwestern, UT Houston, University of
California, San Francisco, and University of California, Los Angeles) have larger catchment
populations so have planned enrollment of 800 subjects per site. Due to heterogeneity in baseline characteristics among study subjects identified early in the study, we modified the enrollment to support a 1:1 case/control ratio at each site, to better enable the comparison of ‘like’
cases with ‘like’ controls.
We estimated the power to detect relative differences in outcome rates between those who
are symptomatic and test positive for SARS-CoV-2 as compared to those who are symptomatic
but test negative for SARS-CoV-2. These power calculations are agnostic to the outcome of
interest but based on the aim to examine relative differences in long-term outcomes between
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Table 4. Event rate difference between groups.
0.07 vs 0.05

0.10 vs 0.05

0.15 vs 0.05

0.20 vs. 0.05

Power

Total N

COVID (+)

COVID (-)

Total N

COVID (+)

COVID (-)

Total N

COVID (+)

COVID (-)

Total N

COVID (+)

0.9

8012

6009

2003

1592

1194

398

516

387

129

180

135

COVID (-)
45

0.8

6076

4557

1519

1224

918

306

404

303

101

144

108

36

0.7

4844

3633

1211

988

741

247

332

249

83

120

90

30

0.6

3904

2928

976

808

606

202

272

204

68

100

75

25

https://doi.org/10.1371/journal.pone.0264260.t004

individuals with and without SARS-CoV-2 based on and between age strata. Prior to changing
the enrollment strategy to a 1:1 case/control ratio, we reran the power analysis. These findings
showed that with 1:1 enrollment, we had increased power to find a difference between SARS-CoV-2 infected vs. uninfected participants. For comparison of ME/CFS incidence in SARS-CoV-2 infected vs. uninfected, power calculations are based on the null hypothesis that there is
no difference between individuals with and without SARS-CoV-2 in the outcome rate.
The assumptions used to generate these power calculations include both elements outside
the study’s team’s control (e.g., baseline outcome rate in individuals without SARS-CoV-2) as
well as elements amenable to changes in study design (e.g., individuals with SARS-CoV-2
strata group size). Assumptions include:
• 3,600 individuals with SARS-CoV-2 and 1,200 individuals without SARS-CoV-2
• Baseline outcome rate in individuals without SARS-CoV-2: 2.5% with the contingency that
the baseline outcome rate may vary between age strata (18–40 years, 41–64 years, � 65
years)
• Outcome rate in individuals with SARS-CoV-2: presented as scenarios based on absolute or
relative differences from baseline outcome rate in individuals without SARS-CoV-2. Also
presented under the likely scenario that outcome rates vary between age strata
• Alpha = 0.05 (fixed)
Under conservative assumptions, the planned sample has 97.8% power to detect an absolute
outcome rate difference of 2.5% between individuals with versus without SARS-CoV-2 infection. The power to detect a relative difference in outcome rates is highly sensitive to both the
actual baseline outcome rate as well as variation in baseline outcome rates between age strata.
The study would have adequate power (conventionally defined as 0.8) to detect a difference as
small as 5% in outcomes with 1,224 total participants (25.5% of total planned enrollment)
enrolled in a 3:1 ratio, or 918 COVID+ and 306 COVID negative (Table 4).

Statistical methods
Statistical analyses will describe disease course and outcomes, including the characterization of
specific symptoms and duration of symptoms (including duration of symptoms prior to
enrollment), health care utilization (emergency department, hospitalization, post-acute care)
with clinical (morbidity/mortality) and patient-reported health status outcomes as well as
recovery (early and late disease sequelae). Baseline and demographic characteristics will be
summarized by descriptive summaries (e.g., means and standard deviations for continuous
variables such as age and percentages for categorical variables such as gender, medians, and
quartiles for skewed data) and will be assessed by site of enrollment and compared to regional
demographic data to evaluate for potential selection bias relative to site-specific patient populations and to assess for representativeness of the local population. Analyses will:
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• Compare health status at baseline and follow-up between persons in the same age group who
test SARS-CoV-2 positive and negative at initial test.
• Characterize health care utilization (ambulatory and ED visits, hospitalizations, post-acute
care, telehealth visits) among SARS-CoV-2 positive participants by age and compare these to
SARS-CoV-2 negative participants.
• Characterize and compare health outcomes by age and SARS-CoV-2 status: emergency or ambulatory care, admission to hospital); ICU-free survival; hospital-free survival; and subsequent
patient-reported health status (cognition; physical health; mental health; and return to work).
We will use statistical modeling to estimate the association between key covariates and outcomes, including evaluating interactions by age. We plan to use survival analysis techniques to
analyze time to outcome events, logistic regression for binary outcomes (e.g., hospitalization
versus no hospitalization), Poisson or Cox regression for count data (e.g., number of hospitalizations over time), and linear regression models for continuous outcomes (e.g., PROMIS-29).
Multiple imputation will be considered to handle missing covariate and outcome data in these
analyses [43]. Chained equations will be used to impute each variable with missing data. Sensitivity analyses will be conducted using missing categories for covariates and including only
people with non-missing outcome information.
We will use statistical analyses to compare the risk of ME/CFS and other health conditions
in those with versus without SARS-CoV-2 infection as risk differences, risk ratios or odds
ratios, as appropriate. Depending on the specific analysis question, we will also match or adjust
for additional patient-level factors of interest, such as age, sex, race/ethnicity, income, and
presence of specific underlying conditions such as hypertension and diabetes. Additional
covariates of interest available from electronic record data will be assessed for their association
with adverse outcomes.

Data monitoring
Periodic reports of de-identified data from participants at each site are exported from the
Hugo data management system for monitoring and analysis by the study cores. These data will
be used to monitor the adequacy of recruitment, with due consideration to the balance of subjects with positive versus negative tests as well as their age distribution, and completeness of
follow-up questionnaires.

Reporting
The results of this study will be reported using the STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) guidelines for reporting observational studies [44]. We intend
to disseminate the results as rapidly as possible to help contribute to the COVID-19 response.

Research partnership
This study is conducted in collaboration with colleagues from the CDC. Scientists from the
CDC assisted with study design and will remain engaged as we evaluate and disseminate the
research findings.

Discussion
Expected key results
Our prospective cohort study is designed to gain critical information needed by clinicians in
the USA and globally regarding medium and long-term sequelae of SARS-CoV-2 infection.
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Prior limited experience with people infected with SARS-CoV-2 suggests that age as well as
race and ethnicity are important risk factors for SARS-CoV 2 infection and for poor outcomes
in the acute setting [20, 45–48]), but there remains limited information concerning predictors
of medium- and long-term outcomes. Moreover, there is a need to leverage digital assets and
tools to harness data from both patients and providers to quickly define the clinical epidemiology of COVID-19. Creating such a platform and assessing its value to address priority questions would have immense significance for the nation.
To date, there has been a relative lack of epidemiological studies designed to provide robust
evidence of incidence, risk factors, and natural history of sequelae of SARS-CoV-2 infection.
Existing studies are limited by multiple potential biases in study design. Many prior studies of
SARS-CoV-2 infection recruited from single rather than multiple centers, which may overestimate the relationship between baseline factors as well as treatment exposures and outcome
and thereby lack generalizability [49–51]. In addition, many have preferentially recruited
patients who are hospitalized or receive intensive care, who have greater acuity or severity of
illness and could be at greater risk of long-term sequelae than those who are treated in an
ambulatory setting. In contrast, our recruitment of participants testing for SARS-CoV-2 with
acute symptoms of illness from community (e.g. drive up testing sites), clinic, emergency, and
in-patient settings reduces the likelihood of selection bias [52].
Prior studies which lack concurrent controls who have similar symptoms or require similar
health care utilization characterize the burden of SARS-CoV-2 infection, but, by the nature of
their design, cannot describe the relative risk of sequelae compared to those who do not have
SARS-CoV-2 infection but who have another viral infection. Social isolation and receipt of
intensive care are both associated with initial and long -term social, emotional, well-being and
health sequelae [53, 54]. The effects of increased social isolation affecting individuals’ social,
emotional, and functional well-being regardless of infection with SARS-CoV-2, further
emphasizes the need for including individuals not infected with SARS-CoV-2 to generate evidence on the incidence of sequelae of COVID-19 illness.
Increasing evidence suggests that a significant proportion of individuals infected with
SARS-CoV-2 experience ongoing clinical symptoms several months after acute infection.
Among a cohort of 4,182 participants testing positive for SARS-CoV-2 evaluated in the
COVID Symptom Study with the majority from the UK (88%), the US (7%), and Sweden
(4.5%), 13% reported symptoms greater than 28 days after onset, with fatigue (98%) and headaches (91%) the most commonly reported symptoms [55]. Additionally, 4.5% of all participants had � 56 days of symptoms and 2.6% had � 84 days of symptoms [55]. In a large
prospective cohort study from Wuhan, China, with in-person evaluations of 1,733 patients at 6
months from symptom onset, 76% of patients reported at least one symptom with the most
commonly reported symptoms being fatigue/muscular weakness (63%), sleep disturbance
(26%), and anxiety/depression (23%) [56]. Among a cohort of 180 participants in the Faroe
Islands who had reverse transcription-polymerase chain reaction positive COVID-19 tests,
53% reported persistence of at least one symptom after a mean of 125 days from symptom
onset [57]; the most persistent severe symptoms reported were fatigue, loss of smell and taste,
and arthralgias [57]. In Italy, among 143 patients discharged from the hospital after acute
COVID-19 with a mean follow-up of 60 days from first symptom onset, 87% of patients had
persistent symptoms with the predominant symptoms being fatigue (53%), dyspnea (43%),
arthralgia (27%), and chest pain, (22%) and with 44% experiencing a worsening quality of life
[58]. A US-based study using historical comparator groups with viral lower respiratory tract
illness and propensity matching demonstrated that 14% of adults � 65 infected with SARS-CoV-2 had at least one new clinical sequelae requiring medical care after the acute phase of the
illness; this was nearly 5 percentage points higher than the historical comparator group [59].
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Similar findings of persistent symptoms have been reported in other studies across the world
[12, 60].
Studies have also reported changes in renal function, metabolic response, cardiovascular
systems, and neurological changes persisting in the post-acute phase of SARS-CoV-2 infection
[61]. Of note, a considerable proportion of those previously infected with SARS-CoV-2
develop new clinical sequelae that were not present during the acute illness and that require
medical attention; new clinical sequelae include chronic respiratory failure, cardiac arrhythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia, diabetes, liver test
abnormalities, myocarditis, anxiety and fatigue [62]. There remains uncertainty regarding the
incidence of sequelae, the range of impacts on individuals, the factors associated with risk for
development of sequelae, and the natural history/time course of the sequelae. Given the high
global rate of SARS-CoV-2 infection, this information is critical to guide care following
SARS-CoV-2 infection amongst vast numbers of individuals. This evidence could potentially
highlight individuals at higher risk for complications who may require more intensive followup and facilitate earlier intervention and guide targeting of primary or secondary interventions
[63]. Further, dissemination of findings from this research may increase COVID-19 vaccination acceptance, helping to prevent sequelae from SARS-CoV-2 infection.

Strengths and limitations
Our cohort study integrates detailed self-reports of participants with automated capture of
their EHR information to provide more comprehensive data than traditional approaches. This
innovative method enables capturing of baseline medical conditions, accounting for intermediate events between SARS-CoV-2 infection and sequelae, and objective assessments over
time. Merging self-reported and digital data in this manner paves the way for similar research
into long-term sequelae in other disease entities, including non-infectious illnesses such as
trauma.
Using the on-line digital platform to collect patient-oriented outcomes enables us to adapt
the survey content in real time as new information emerges. For example, we adapted the survey when vaccines became available. Additionally, there is the potential for this cohort to be
engaged in future research as new questions arise relating to long-term sequalae, therapies and
other related issues. Recruitment design strengths include the inclusion of participants with a
range of disease severity, including participants with and without a history of hospitalization.
Additionally, we seek to recruit participants who are ethnically diverse and geographically dispersed. Further, our design includes concurrent controls with negative SARS-CoV-2 diagnostic results to overcome the variable exposure to healthcare access as well as to COVID-19
mitigation strategies implemented in the community (e.g., masking mandates, shut-downs)
which could otherwise bias assessment of the risk of patient-reported outcomes. Finally, our
planned sample size will enable detection of rare events among the study population.
Our design anticipates and addresses study limitations as feasible. First, inclusion in the
INSPIRE study requires participants to have a sufficient degree of technology literacy as well as
periodic access to the internet which may introduce selection bias into who is able to participate. There are large differences in the use of desktop or laptop computers between Black
(58%) or Hispanic or Latino persons (57%) vs. White (82%) individuals [64]. Importantly,
about 80% of Black, Hispanic or Latino persons, and White adults own a smartphone; lack of
availability of a smartphone should not be a barrier to enrollment of racial/ethnic subgroups in
this study. We worked to overcome challenges related to technology literacy by offering support at the time of enrollment and throughout the study to troubleshoot problems such as linking digital health portals to the Hugo platform and completing quarterly surveys. Second,
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while medium and long-term sequelae of SARS-CoV-2 infection can occur following asymptomatic infection, we made the decision not to enroll asymptomatic individuals and thus will
not be able to report on outcomes in this group. We anticipate that individuals with COVID19 and symptomatic illness are more likely to have the outcomes of interest. Third, there is the
potential for selection bias in which participants whose COVID-19 illness has not yet resolved
are more likely to enroll in this study. To mitigate against this, we required that enrollment
occurwithin 42 days of SARS-CoV-2 infection diagnosis. At the analysis stage, sensitivity analysis can describe long-term symptoms as a function of time between onset and enrollment.
Fourth, given the prospective longitudinal design of this study, there is an inherent risk of
attrition and loss-to-follow-up of participants. To limit this potential problem, each research
site monitors research participants’ progress and invites them to re-engage if they do not complete their quarterly survey. While the preferred means of contact varies between sites, this
may include through email, short message service (i.e., text), or telephone reminder. Additionally, participants are incentivized to participate with a monetary reward for survey completion
as described above (consent and ethics section).
Fifth, there is a risk of poor data quality and misclassification. With this study design which
incorporates digital health data, some data is passively acquired and thereby data quality is
dependent on the linkage to and capture of electronic medical records. We believe that coupling these digital health data with the self-reported data will enhance the accuracy and completeness of available information. There is also potential for bias from unmasking underlying
health conditions identified during the study that were not known until after the SARS-CoV-2
infection resulting in misclassification of pre-existing diagnoses as sequelae of COVID-19. As
feasible, we will evaluate indications of undiagnosed health conditions by evaluating data from
the EHR.
Sixth, is the risk of misclassification bias from inaccurate diagnostic test results of COVID19 tests at enrollment. Despite the reported high sensitivity and specificity of SARS-CoV-2
diagnostic testing [65, 66], some participants could be misclassified as having or not having
acute SARS-CoV-2 infection. Participants with false negative test results are classified as controls but can still have increased risks of long-term sequelae, which may bias our results
towards the null. As well, participants’ SARS-CoV-2 status can change over time due to repeat
exposure and repeat diagnostic testing. We inquire about repeat SARS-CoV-2 testing and
results during quarterly surveys and we will also look for related data during electronic medical
record review.

Conclusions
Upon the conclusion of the study, we will be able to quantify the burden of long-term SARS-CoV-2 sequelae as well as characterize predictors of sequelae. Additionally, data from INSPIRE
will offer insight into syndromes with overlapping signs and symptoms, such as ME/CFS, as
well as how people with underlying disease and subsequent COVID-19 experience these illnesses. We will be better poised to develop prevention and treatment strategies and to tailor
these strategies for the most at-risk subsets of the population. The results will inform clinicians
and public health authorities and will help prepare for future SARS-CoV-2 surges.
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the Faroe Islands—a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020. https://
doi.org/10.1093/cid/ciaa1792 PMID: 33252665

58.

Carfı̀ A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent
Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324: 603–605. https://doi.org/10.1001/
jama.2020.12603 PMID: 32644129

59.

Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical
sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021; 373:
n1098. https://doi.org/10.1136/bmj.n1098 PMID: 34011492

60.

Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;
27: 258–263. https://doi.org/10.1016/j.cmi.2020.09.052 PMID: 33031948

61.

Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26: 1017–1032. https://doi.org/10.1038/s41591-020-0968-3 PMID:
32651579

62.

Daugherty SE, Guo Y, Heath K, Dasmarinas MC, Jubilo KG, Samranvedhya J, et al. SARS-CoV-2
infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study. medRxiv. 2021 [accessed 14 December 2021]. Available: https://www.medrxiv.org/content/10.1101/2021.03.
12.21253448v1.abstract

63.

Curci C, Pisano F, Bonacci E, Camozzi DM, Ceravolo C, Bergonzi R, et al. Early rehabilitation in postacute COVID-19 patients: data from an Italian COVID-19 rehabilitation unit and proposal of a treatment
protocol. A cross-sectional study. Eur J Phys Rehabil Med. 2020; 56: 633–641. https://doi.org/10.
23736/S1973-9087.20.06339-X PMID: 32667150

64.

Perrin A, Turner E. Smartphones help blacks, Hispanics bridge some—but not all—digital gaps with
whites. Aug 20, 2019.

65.

Dong L, Zhou J, Niu C, Wang Q, Pan Y, Sheng S, et al. Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR. https://doi.org/10.1101/2020.03.14.20036129

PLOS ONE | https://doi.org/10.1371/journal.pone.0264260 March 3, 2022

18 / 19

PLOS ONE

INSPIRE study

66.

Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat Microbiol. 2020; 5: 1299–1305.
https://doi.org/10.1038/s41564-020-0761-6 PMID: 32651556

PLOS ONE | https://doi.org/10.1371/journal.pone.0264260 March 3, 2022

19 / 19

